Pharmacovigilance Requirements for NCD Medicines

The article emphasizes that pharmacovigilance for noncommunicable disease medicines must be continuous, product-specific, and grounded in real-world use because these medicines are often taken for years or lifelong. It explains that clinical trials cannot detect all long-term, rare, cumulative, or interaction-related risks, especially among patients with multimorbidity, polypharmacy, organ impairment, pregnancy, or other vulnerabilities. Pharmaceutical companies should therefore strengthen safety systems through risk-management planning, high-quality adverse-event reporting, active surveillance, real-world evidence, targeted clinical monitoring, signal management, risk communication, and product-quality oversight. Overall, the article frames pharmacovigilance not as a compliance exercise, but as a scientific and ethical responsibility to detect preventable harm early while preserving access to beneficial NCD treatment.